Tests a new heart mapping and ablation system for paroxysmal atrial fibrillation
Tests a domestic mapping and catheter system to treat paroxysmal atrial fibrillation in adults.
Plain-language title generated from the registry record
Registry title: A Clinical Study on the Use of a Domestically Produced Three-dimensional Cardiac Electrophysiological Mapping System Combined With Pressure Monitoring Technology and Star Mapping Technology for the Treatment of Paroxysmal Atrial Fibrillation.
Key facts
- Where
- Chengdu, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07039032, who can take part
Where in China
- West China Hospital of Sichuan UniversityChengdu, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai MicroPort EP MedTech Co., Ltd.
- Trial code
- NCT07039032
- Record updated
- 27 June 2025
- Original description
Validating the safety and efficacy of pressure monitoring technology and star-shaped marking technology for the treatment of paroxysmal atrial fibrillationRead full original descriptionShow less
A Clinical Study on the Use of a Domestically Produced Three-dimensional Cardiac Electrophysiological Mapping System Combined With Pressure Monitoring Technology and Star Mapping Technology for the Treatment of Paroxysmal Atrial Fibrillation.
Validating the safety and efficacy of pressure monitoring technology and star-shaped marking technology for the treatment of paroxysmal atrial fibrillation
Inclusion: Patient age between 18 and 80 years old, male or non-pregnant female; Confirmed diagnosis of paroxysmal atrial fibrillation requiring catheter radiofrequency ablation surgery; Fully understands the treatment plan and voluntarily signs the informed consent form, willing to undergo the examinations, surgery, and follow-up required by the plan.
Exclusion: History of atrial septal defect repair or atrial myxoma; History of cerebrovascular disease within the past 3 months (including stroke or transient ischaemic attack); History of cardiovascular events within the past 3 months (including acute myocardial infarction, coronary artery intervention or bypass surgery, artificial valve replacement or repair, or atrial or ventricular incision); Patients with acute or severe systemic infection; Patients with severe liver or kidney disease; Patients with significant bleeding tendencies or haematological disorders; Patients with malignant tumours or end-stage diseases; Left atrial size ≥50 mm, left ventricular ejection fraction ≤40%; Reproductive-age patients who cannot use effective contraception within 12 months of enrolment; Post-ablation for atrial fibrillation; Left atrial thrombus; Patients deemed ineligible for this trial by the investigator.